Alexion Pharmaceuticals Inc (ALXN.O) News| Reuters.com
Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

114.94USD
28 Jun 2016
Change (% chg)

$3.05 (+2.73%)
Prev Close
$111.89
Open
$113.00
Day's High
$115.69
Day's Low
$113.00
Volume
2,299,132
Avg. Vol
1,765,534
52-wk High
$208.88
52-wk Low
$110.56

Select another date:

Fri, Jun 10 2016

BRIEF-Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210

* Late-Breaking data presented at EHA: all patients with pnh treated with once-monthly dosing of ALXN1210 in phase 1/2 study exhibit rapid and sustained reductions in ldhSays announced today that interim data were presented from a phase 1/2 study of ALXN1210

Alexion shares slump as drug misses goal in late-stage trial

Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.

UPDATE 1-Alexion shares slump as drug misses goal in late-stage trial

June 6 Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.

Alexion drug misses goal in late-stage trial

June 6 Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial, sending its shares down 9 percent in extended trade.

BRIEF-Alexion announces topline results from Phase 3 regain study of eculizumab

* Alexion announces topline results from Phase 3 regain study of eculizumab (soliris) in patients with refractory generalized myasthenia gravis (GMG)

BRIEF-Alexion says CEO David Hallal's 2015 compensation was $14.7 mln

* Says CFO Vikas Sinha FY 2015 total compensation $4.7 million versus $7 million in FY 2014 - sec filing

BRIEF-Alexion Pharmaceuticals Kanuma receives marketing approval in Japan

* Kanuma receives marketing approval in japan for treatment of patients with lysosomal acid lipase deficiency Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

UK cost agency queries value of $700,000-a-year Alexion drug

LONDON An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.

UPDATE 1-UK cost agency queries value of $700,000-a-year Alexion drug

LONDON, Feb 18 An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.

UK cost agency queries value of $700,000-a-year Alexion drug

LONDON, Feb 18 An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.

Select another date: